Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Christopher D, Lao"'
Autor:
Alexander M. Balinski, Alexi L. Vasbinder, Connor C. Kerndt, Tonimarie C. Catalan, Nathan P. Parry, Rafey A. Rehman, Pennelope Blakely, Raymond Y. Yeow, Monika J. Leja, Christopher D. Lao, Leslie A. Fecher, Salim S. Hayek
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2356-2367 (2023)
Abstract Background Cardiac metastasis of melanoma is rare and typically diagnosed post‐mortem. Here we perform a retrospective cohort study and systematic review of patients with metastatic melanoma to characterize prevalence, clinical characteris
Externí odkaz:
https://doaj.org/article/923ccc9b39a64ccc8c8887ffde6c4197
Autor:
Morgan Homan, Govind Warrier, Christopher D. Lao, Sarah Yentz, Shawna Kraft, Leslie A. Fecher
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Combination dabrafenib (D) and trametinib (T) is an FDA approved adjuvant therapy for patients with resected stage III BRAF-mutant melanoma. We describe treatment-related toxicities with adjuvant D+T in a real-world population through a retrospective
Externí odkaz:
https://doaj.org/article/cbccc85ea7e8455ba727545ee78d4caf
Autor:
Vincent T. Ma, Alahendra A. Chamila Perera, Yilun Sun, Merna Sitto, Jessica J. Waninger, Govind Warrier, Michael D. Green, Leslie A. Fecher, Christopher D. Lao
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundStandard combination ipilimumab/nivolumab (I/N) is given as 4 induction doses for advanced stage melanoma followed by nivolumab single-agent maintenance therapy. While many patients receive less than 4 doses due to immune-related toxicities
Externí odkaz:
https://doaj.org/article/24f277d92c434e08b89fee9a38e49630
Autor:
Caitlin A. Schonewolf, MD, MSCTS, Elizabeth M. Jaworski, MD, Steven G. Allen, MD, PhD, Karen McLean, MD, Christopher D. Lao, MD, Lynn M. Schuchter, MD, Janos Tanyi, MD, PhD, Neil K. Taunk, MD, MSCTS
Publikováno v:
Advances in Radiation Oncology, Vol 7, Iss 2, Pp 100839- (2022)
Externí odkaz:
https://doaj.org/article/ee581f623dc4407fa1f8f67bd9f2e6e0
Autor:
Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen, Melissa Hamilton, Shien Guo, Ling Shi, Sarah Keidel, Georgina V. Long
Publikováno v:
European Journal of Cancer. 187:164-173
Background: In the phase II/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO + RELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63f0f4f8612f517dcdf203d0a5aa768
https://doi.org/10.1016/j.ejca.2023.03.014
https://doi.org/10.1016/j.ejca.2023.03.014
Autor:
Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable resp
Externí odkaz:
https://doaj.org/article/2501d6126ef24a80bcbed81058801563
Autor:
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Publikováno v:
New England Journal of Medicine. 388:813-823
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::572c5454e442063325a108f2b1da3b9a
https://doi.org/10.1056/nejmoa2211437
https://doi.org/10.1056/nejmoa2211437
Autor:
Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in p
Externí odkaz:
https://doaj.org/article/5cdc7070ed8046e696ecf169baa8612b
Autor:
Alexi Vasbinder, YeeAnn Chen, Adrien Procureur, Allison Gradone, Tariq U. Azam, Daniel Perry, Husam Shadid, Elizabeth Anderson, Tonimarie Catalan, Pennelope Blakely, Namratha Nelapudi, Mohamad Fardous, Marie C. Bretagne, Sarah K. Adie, Kristen T. Pogue, Monika Leja, Sarah Yentz, Bryan Schneider, Leslie A. Fecher, Christopher D. Lao, Joe-Elie Salem, Salim S. Hayek
Publikováno v:
JACC: CardioOncology. 4:689-700
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8a4bf51b33e5aeb3e02e41241502307
https://doi.org/10.1016/j.jaccao.2022.11.004
https://doi.org/10.1016/j.jaccao.2022.11.004
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and
Externí odkaz:
https://doaj.org/article/369c8eef082e487e8b1ee700e6160944